nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydroxychloroquine—Halo vision—Vandetanib—thyroid cancer	0.136	0.173	CcSEcCtD
Hydroxychloroquine—Corneal deposits—Vandetanib—thyroid cancer	0.0537	0.0682	CcSEcCtD
Hydroxychloroquine—Abnormal pigmentation—Epirubicin—thyroid cancer	0.0259	0.0329	CcSEcCtD
Hydroxychloroquine—Abnormal pigmentation—Doxorubicin—thyroid cancer	0.024	0.0305	CcSEcCtD
Hydroxychloroquine—Visual acuity reduced—Vandetanib—thyroid cancer	0.0165	0.0209	CcSEcCtD
Hydroxychloroquine—Oropharyngeal discomfort—Sorafenib—thyroid cancer	0.0091	0.0116	CcSEcCtD
Hydroxychloroquine—TLR7—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—CDK1—thyroid cancer	0.00819	0.0385	CbGpPWpGaD
Hydroxychloroquine—TLR7—MyD88 dependent cascade initiated on endosome—CDK1—thyroid cancer	0.00804	0.0378	CbGpPWpGaD
Hydroxychloroquine—TLR7—Toll Like Receptor 9 (TLR9) Cascade—CDK1—thyroid cancer	0.00776	0.0365	CbGpPWpGaD
Hydroxychloroquine—Dermatitis bullous—Vandetanib—thyroid cancer	0.00745	0.00946	CcSEcCtD
Hydroxychloroquine—Pigmentation disorder—Epirubicin—thyroid cancer	0.00732	0.0093	CcSEcCtD
Hydroxychloroquine—Cardiac failure—Vandetanib—thyroid cancer	0.00729	0.00927	CcSEcCtD
Hydroxychloroquine—Hypoglycaemia—Vandetanib—thyroid cancer	0.00729	0.00927	CcSEcCtD
Hydroxychloroquine—TLR7—Toll-like Receptor Signaling Pathway—IFNA2—thyroid cancer	0.00687	0.0323	CbGpPWpGaD
Hydroxychloroquine—Pigmentation disorder—Doxorubicin—thyroid cancer	0.00678	0.00861	CcSEcCtD
Hydroxychloroquine—TLR9—IRS-mediated signalling—CDK1—thyroid cancer	0.00653	0.0307	CbGpPWpGaD
Hydroxychloroquine—TLR9—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—CDK1—thyroid cancer	0.00647	0.0304	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-related events—CDK1—thyroid cancer	0.00635	0.0299	CbGpPWpGaD
Hydroxychloroquine—TLR9—MyD88 dependent cascade initiated on endosome—CDK1—thyroid cancer	0.00635	0.0299	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-related events triggered by IGF1R—CDK1—thyroid cancer	0.0063	0.0296	CbGpPWpGaD
Hydroxychloroquine—Bullous eruption—Epirubicin—thyroid cancer	0.00619	0.00786	CcSEcCtD
Hydroxychloroquine—TLR9—IGF1R signaling cascade—CDK1—thyroid cancer	0.00613	0.0288	CbGpPWpGaD
Hydroxychloroquine—TLR9—Toll Like Receptor 9 (TLR9) Cascade—CDK1—thyroid cancer	0.00613	0.0288	CbGpPWpGaD
Hydroxychloroquine—TLR9—Insulin receptor signalling cascade—CDK1—thyroid cancer	0.00613	0.0288	CbGpPWpGaD
Hydroxychloroquine—Bronchospasm—Vandetanib—thyroid cancer	0.00605	0.00769	CcSEcCtD
Hydroxychloroquine—Leukoderma—Epirubicin—thyroid cancer	0.00575	0.00731	CcSEcCtD
Hydroxychloroquine—Bullous eruption—Doxorubicin—thyroid cancer	0.00572	0.00727	CcSEcCtD
Hydroxychloroquine—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00562	0.00713	CcSEcCtD
Hydroxychloroquine—Weight decreased—Vandetanib—thyroid cancer	0.00557	0.00707	CcSEcCtD
Hydroxychloroquine—TLR7—Toll-Like Receptors Cascades—CDK1—thyroid cancer	0.00551	0.0259	CbGpPWpGaD
Hydroxychloroquine—Hepatic function abnormal—Sorafenib—thyroid cancer	0.00549	0.00698	CcSEcCtD
Hydroxychloroquine—Depression—Vandetanib—thyroid cancer	0.00547	0.00695	CcSEcCtD
Hydroxychloroquine—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00544	0.00691	CcSEcCtD
Hydroxychloroquine—TLR9—Toll-like Receptor Signaling Pathway—IFNA2—thyroid cancer	0.00543	0.0255	CbGpPWpGaD
Hydroxychloroquine—TLR7—Regulation of toll-like receptor signaling pathway—IFNA2—thyroid cancer	0.00536	0.0252	CbGpPWpGaD
Hydroxychloroquine—Leukoderma—Doxorubicin—thyroid cancer	0.00532	0.00676	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling by Insulin receptor—CDK1—thyroid cancer	0.00509	0.0239	CbGpPWpGaD
Hydroxychloroquine—Dermatitis exfoliative—Sorafenib—thyroid cancer	0.00509	0.00647	CcSEcCtD
Hydroxychloroquine—Haemoglobin—Vandetanib—thyroid cancer	0.00495	0.00629	CcSEcCtD
Hydroxychloroquine—Haemorrhage—Vandetanib—thyroid cancer	0.00492	0.00626	CcSEcCtD
Hydroxychloroquine—Cardiac failure—Sorafenib—thyroid cancer	0.00492	0.00625	CcSEcCtD
Hydroxychloroquine—Cardiomyopathy—Epirubicin—thyroid cancer	0.00478	0.00607	CcSEcCtD
Hydroxychloroquine—Visual impairment—Vandetanib—thyroid cancer	0.00475	0.00603	CcSEcCtD
Hydroxychloroquine—Erythema multiforme—Vandetanib—thyroid cancer	0.00466	0.00592	CcSEcCtD
Hydroxychloroquine—Eye disorder—Vandetanib—thyroid cancer	0.0046	0.00585	CcSEcCtD
Hydroxychloroquine—Mood swings—Sorafenib—thyroid cancer	0.00455	0.00578	CcSEcCtD
Hydroxychloroquine—Cardiomyopathy—Doxorubicin—thyroid cancer	0.00442	0.00562	CcSEcCtD
Hydroxychloroquine—Abdominal pain upper—Sorafenib—thyroid cancer	0.00439	0.00557	CcSEcCtD
Hydroxychloroquine—TLR9—Toll-Like Receptors Cascades—CDK1—thyroid cancer	0.00436	0.0205	CbGpPWpGaD
Hydroxychloroquine—Alopecia—Vandetanib—thyroid cancer	0.00435	0.00553	CcSEcCtD
Hydroxychloroquine—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00432	0.00549	CcSEcCtD
Hydroxychloroquine—Mental disorder—Vandetanib—thyroid cancer	0.00431	0.00548	CcSEcCtD
Hydroxychloroquine—Malnutrition—Vandetanib—thyroid cancer	0.00429	0.00545	CcSEcCtD
Hydroxychloroquine—TLR9—Regulation of toll-like receptor signaling pathway—IFNA2—thyroid cancer	0.00424	0.0199	CbGpPWpGaD
Hydroxychloroquine—Vision blurred—Vandetanib—thyroid cancer	0.00404	0.00513	CcSEcCtD
Hydroxychloroquine—Eruption—Epirubicin—thyroid cancer	0.00397	0.00505	CcSEcCtD
Hydroxychloroquine—Psoriasis—Epirubicin—thyroid cancer	0.00389	0.00494	CcSEcCtD
Hydroxychloroquine—Loss of consciousness—Vandetanib—thyroid cancer	0.00377	0.00479	CcSEcCtD
Hydroxychloroquine—Weight decreased—Sorafenib—thyroid cancer	0.00375	0.00477	CcSEcCtD
Hydroxychloroquine—Convulsion—Vandetanib—thyroid cancer	0.00371	0.00472	CcSEcCtD
Hydroxychloroquine—Eruption—Doxorubicin—thyroid cancer	0.00368	0.00467	CcSEcCtD
Hydroxychloroquine—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00367	0.00466	CcSEcCtD
Hydroxychloroquine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00362	0.0046	CcSEcCtD
Hydroxychloroquine—Bone marrow depression—Epirubicin—thyroid cancer	0.00362	0.0046	CcSEcCtD
Hydroxychloroquine—Hypokinesia—Epirubicin—thyroid cancer	0.00362	0.0046	CcSEcCtD
Hydroxychloroquine—Psoriasis—Doxorubicin—thyroid cancer	0.0036	0.00457	CcSEcCtD
Hydroxychloroquine—Paralysis—Epirubicin—thyroid cancer	0.00352	0.00447	CcSEcCtD
Hydroxychloroquine—Oedema—Vandetanib—thyroid cancer	0.0035	0.00444	CcSEcCtD
Hydroxychloroquine—Nervous system disorder—Vandetanib—thyroid cancer	0.00343	0.00436	CcSEcCtD
Hydroxychloroquine—Thrombocytopenia—Vandetanib—thyroid cancer	0.00343	0.00435	CcSEcCtD
Hydroxychloroquine—Nystagmus—Epirubicin—thyroid cancer	0.00342	0.00435	CcSEcCtD
Hydroxychloroquine—Skin disorder—Vandetanib—thyroid cancer	0.0034	0.00432	CcSEcCtD
Hydroxychloroquine—Bone marrow depression—Doxorubicin—thyroid cancer	0.00335	0.00426	CcSEcCtD
Hydroxychloroquine—Hypokinesia—Doxorubicin—thyroid cancer	0.00335	0.00426	CcSEcCtD
Hydroxychloroquine—Haemoglobin—Sorafenib—thyroid cancer	0.00334	0.00424	CcSEcCtD
Hydroxychloroquine—Haemorrhage—Sorafenib—thyroid cancer	0.00332	0.00422	CcSEcCtD
Hydroxychloroquine—Paralysis—Doxorubicin—thyroid cancer	0.00326	0.00414	CcSEcCtD
Hydroxychloroquine—Scotoma—Epirubicin—thyroid cancer	0.00322	0.00409	CcSEcCtD
Hydroxychloroquine—Nystagmus—Doxorubicin—thyroid cancer	0.00317	0.00402	CcSEcCtD
Hydroxychloroquine—Erythema multiforme—Sorafenib—thyroid cancer	0.00314	0.00399	CcSEcCtD
Hydroxychloroquine—Tinnitus—Sorafenib—thyroid cancer	0.0031	0.00393	CcSEcCtD
Hydroxychloroquine—Decreased appetite—Vandetanib—thyroid cancer	0.00304	0.00386	CcSEcCtD
Hydroxychloroquine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00302	0.00384	CcSEcCtD
Hydroxychloroquine—Fatigue—Vandetanib—thyroid cancer	0.00302	0.00383	CcSEcCtD
Hydroxychloroquine—Pain—Vandetanib—thyroid cancer	0.00299	0.0038	CcSEcCtD
Hydroxychloroquine—Scotoma—Doxorubicin—thyroid cancer	0.00298	0.00378	CcSEcCtD
Hydroxychloroquine—Alopecia—Sorafenib—thyroid cancer	0.00294	0.00373	CcSEcCtD
Hydroxychloroquine—Blood disorder—Epirubicin—thyroid cancer	0.00293	0.00372	CcSEcCtD
Hydroxychloroquine—Mental disorder—Sorafenib—thyroid cancer	0.00291	0.0037	CcSEcCtD
Hydroxychloroquine—Malnutrition—Sorafenib—thyroid cancer	0.00289	0.00367	CcSEcCtD
Hydroxychloroquine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00286	0.00363	CcSEcCtD
Hydroxychloroquine—Cardiovascular disorder—Epirubicin—thyroid cancer	0.00278	0.00353	CcSEcCtD
Hydroxychloroquine—Body temperature increased—Vandetanib—thyroid cancer	0.00277	0.00351	CcSEcCtD
Hydroxychloroquine—Abdominal pain—Vandetanib—thyroid cancer	0.00277	0.00351	CcSEcCtD
Hydroxychloroquine—Blood disorder—Doxorubicin—thyroid cancer	0.00271	0.00344	CcSEcCtD
Hydroxychloroquine—Skin discolouration—Epirubicin—thyroid cancer	0.00271	0.00344	CcSEcCtD
Hydroxychloroquine—Anaemia—Sorafenib—thyroid cancer	0.00267	0.0034	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—RAP1GAP—thyroid cancer	0.00267	0.0126	CbGpPWpGaD
Hydroxychloroquine—Angioedema—Sorafenib—thyroid cancer	0.00264	0.00336	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—LGALS3—thyroid cancer	0.00261	0.0123	CbGpPWpGaD
Hydroxychloroquine—TLR7—Innate Immune System—PRKAR1A—thyroid cancer	0.00259	0.0122	CbGpPWpGaD
Hydroxychloroquine—Leukopenia—Sorafenib—thyroid cancer	0.00259	0.00329	CcSEcCtD
Hydroxychloroquine—Cardiovascular disorder—Doxorubicin—thyroid cancer	0.00257	0.00327	CcSEcCtD
Hydroxychloroquine—Loss of consciousness—Sorafenib—thyroid cancer	0.00254	0.00323	CcSEcCtD
Hydroxychloroquine—Asthenia—Vandetanib—thyroid cancer	0.00251	0.00319	CcSEcCtD
Hydroxychloroquine—Skin discolouration—Doxorubicin—thyroid cancer	0.0025	0.00318	CcSEcCtD
Hydroxychloroquine—Pruritus—Vandetanib—thyroid cancer	0.00248	0.00314	CcSEcCtD
Hydroxychloroquine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00245	0.00311	CcSEcCtD
Hydroxychloroquine—Hepatocellular injury—Epirubicin—thyroid cancer	0.00244	0.00311	CcSEcCtD
Hydroxychloroquine—Diarrhoea—Vandetanib—thyroid cancer	0.00239	0.00304	CcSEcCtD
Hydroxychloroquine—TLR9—IRS-mediated signalling—NRAS—thyroid cancer	0.00234	0.011	CbGpPWpGaD
Hydroxychloroquine—Nervous system disorder—Sorafenib—thyroid cancer	0.00231	0.00294	CcSEcCtD
Hydroxychloroquine—Dizziness—Vandetanib—thyroid cancer	0.00231	0.00294	CcSEcCtD
Hydroxychloroquine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00231	0.00294	CcSEcCtD
Hydroxychloroquine—Aplastic anaemia—Epirubicin—thyroid cancer	0.0023	0.00292	CcSEcCtD
Hydroxychloroquine—Skin disorder—Sorafenib—thyroid cancer	0.00229	0.00291	CcSEcCtD
Hydroxychloroquine—TLR9—IRS-related events—NRAS—thyroid cancer	0.00228	0.0107	CbGpPWpGaD
Hydroxychloroquine—Hepatocellular injury—Doxorubicin—thyroid cancer	0.00226	0.00287	CcSEcCtD
Hydroxychloroquine—TLR9—IRS-related events triggered by IGF1R—NRAS—thyroid cancer	0.00226	0.0106	CbGpPWpGaD
Hydroxychloroquine—Anorexia—Sorafenib—thyroid cancer	0.00225	0.00286	CcSEcCtD
Hydroxychloroquine—Vomiting—Vandetanib—thyroid cancer	0.00222	0.00283	CcSEcCtD
Hydroxychloroquine—Rash—Vandetanib—thyroid cancer	0.00221	0.0028	CcSEcCtD
Hydroxychloroquine—Dermatitis—Vandetanib—thyroid cancer	0.0022	0.0028	CcSEcCtD
Hydroxychloroquine—TLR9—Insulin receptor signalling cascade—NRAS—thyroid cancer	0.0022	0.0103	CbGpPWpGaD
Hydroxychloroquine—TLR9—IGF1R signaling cascade—NRAS—thyroid cancer	0.0022	0.0103	CbGpPWpGaD
Hydroxychloroquine—Headache—Vandetanib—thyroid cancer	0.00219	0.00278	CcSEcCtD
Hydroxychloroquine—Aplastic anaemia—Doxorubicin—thyroid cancer	0.00212	0.0027	CcSEcCtD
Hydroxychloroquine—TLR9—Immune System—RAP1GAP—thyroid cancer	0.00211	0.00993	CbGpPWpGaD
Hydroxychloroquine—Nausea—Vandetanib—thyroid cancer	0.00208	0.00264	CcSEcCtD
Hydroxychloroquine—TLR9—Innate Immune System—LGALS3—thyroid cancer	0.00207	0.00971	CbGpPWpGaD
Hydroxychloroquine—Decreased appetite—Sorafenib—thyroid cancer	0.00205	0.00261	CcSEcCtD
Hydroxychloroquine—TLR9—Innate Immune System—PRKAR1A—thyroid cancer	0.00205	0.00963	CbGpPWpGaD
Hydroxychloroquine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00204	0.00259	CcSEcCtD
Hydroxychloroquine—Fatigue—Sorafenib—thyroid cancer	0.00203	0.00258	CcSEcCtD
Hydroxychloroquine—Hepatic function abnormal—Epirubicin—thyroid cancer	0.00203	0.00258	CcSEcCtD
Hydroxychloroquine—Photosensitivity—Epirubicin—thyroid cancer	0.00202	0.00257	CcSEcCtD
Hydroxychloroquine—Pain—Sorafenib—thyroid cancer	0.00202	0.00256	CcSEcCtD
Hydroxychloroquine—TLR9—IRS-mediated signalling—KRAS—thyroid cancer	0.00202	0.00948	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-related events—KRAS—thyroid cancer	0.00196	0.00922	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-related events triggered by IGF1R—KRAS—thyroid cancer	0.00194	0.00914	CbGpPWpGaD
Hydroxychloroquine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00193	0.00245	CcSEcCtD
Hydroxychloroquine—TLR9—IGF1R signaling cascade—KRAS—thyroid cancer	0.00189	0.0089	CbGpPWpGaD
Hydroxychloroquine—TLR9—Insulin receptor signalling cascade—KRAS—thyroid cancer	0.00189	0.0089	CbGpPWpGaD
Hydroxychloroquine—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.00188	0.00239	CcSEcCtD
Hydroxychloroquine—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.00188	0.00239	CcSEcCtD
Hydroxychloroquine—Urticaria—Sorafenib—thyroid cancer	0.00187	0.00238	CcSEcCtD
Hydroxychloroquine—Photosensitivity—Doxorubicin—thyroid cancer	0.00187	0.00238	CcSEcCtD
Hydroxychloroquine—Abdominal pain—Sorafenib—thyroid cancer	0.00187	0.00237	CcSEcCtD
Hydroxychloroquine—Body temperature increased—Sorafenib—thyroid cancer	0.00187	0.00237	CcSEcCtD
Hydroxychloroquine—Dermatitis bullous—Epirubicin—thyroid cancer	0.00186	0.00236	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling by Insulin receptor—NRAS—thyroid cancer	0.00183	0.00859	CbGpPWpGaD
Hydroxychloroquine—Hypoglycaemia—Epirubicin—thyroid cancer	0.00182	0.00231	CcSEcCtD
Hydroxychloroquine—Cardiac failure—Epirubicin—thyroid cancer	0.00182	0.00231	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—CDK1—thyroid cancer	0.00179	0.00839	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	0.00176	0.00826	CbGpPWpGaD
Hydroxychloroquine—Affect lability—Epirubicin—thyroid cancer	0.00175	0.00222	CcSEcCtD
Hydroxychloroquine—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00174	0.00221	CcSEcCtD
Hydroxychloroquine—Hypersensitivity—Sorafenib—thyroid cancer	0.00174	0.00221	CcSEcCtD
Hydroxychloroquine—Dermatitis bullous—Doxorubicin—thyroid cancer	0.00172	0.00218	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—IFNA2—thyroid cancer	0.00172	0.00807	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-mediated signalling—HRAS—thyroid cancer	0.00171	0.00806	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—CALCB—thyroid cancer	0.00169	0.00796	CbGpPWpGaD
Hydroxychloroquine—Asthenia—Sorafenib—thyroid cancer	0.00169	0.00215	CcSEcCtD
Hydroxychloroquine—Cardiac failure—Doxorubicin—thyroid cancer	0.00168	0.00214	CcSEcCtD
Hydroxychloroquine—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00168	0.00214	CcSEcCtD
Hydroxychloroquine—Mood swings—Epirubicin—thyroid cancer	0.00168	0.00214	CcSEcCtD
Hydroxychloroquine—Pruritus—Sorafenib—thyroid cancer	0.00167	0.00212	CcSEcCtD
Hydroxychloroquine—Ataxia—Epirubicin—thyroid cancer	0.00167	0.00212	CcSEcCtD
Hydroxychloroquine—TLR9—IRS-related events—HRAS—thyroid cancer	0.00167	0.00784	CbGpPWpGaD
Hydroxychloroquine—TLR7—Toll-like Receptor Signaling Pathway—AKT1—thyroid cancer	0.00166	0.00778	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-related events triggered by IGF1R—HRAS—thyroid cancer	0.00165	0.00777	CbGpPWpGaD
Hydroxychloroquine—Liver function test abnormal—Epirubicin—thyroid cancer	0.00164	0.00208	CcSEcCtD
Hydroxychloroquine—Abdominal pain upper—Epirubicin—thyroid cancer	0.00162	0.00206	CcSEcCtD
Hydroxychloroquine—Affect lability—Doxorubicin—thyroid cancer	0.00162	0.00205	CcSEcCtD
Hydroxychloroquine—Diarrhoea—Sorafenib—thyroid cancer	0.00161	0.00205	CcSEcCtD
Hydroxychloroquine—TLR9—Insulin receptor signalling cascade—HRAS—thyroid cancer	0.00161	0.00756	CbGpPWpGaD
Hydroxychloroquine—TLR9—IGF1R signaling cascade—HRAS—thyroid cancer	0.00161	0.00756	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—TRIM33—thyroid cancer	0.00161	0.00755	CbGpPWpGaD
Hydroxychloroquine—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.0016	0.00203	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling by Insulin receptor—KRAS—thyroid cancer	0.00157	0.00739	CbGpPWpGaD
Hydroxychloroquine—Muscular weakness—Epirubicin—thyroid cancer	0.00157	0.00199	CcSEcCtD
Hydroxychloroquine—Dizziness—Sorafenib—thyroid cancer	0.00156	0.00198	CcSEcCtD
Hydroxychloroquine—Mood swings—Doxorubicin—thyroid cancer	0.00156	0.00198	CcSEcCtD
Hydroxychloroquine—Ataxia—Doxorubicin—thyroid cancer	0.00154	0.00196	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—TPR—thyroid cancer	0.00154	0.00721	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—LGALS3—thyroid cancer	0.00152	0.00715	CbGpPWpGaD
Hydroxychloroquine—Eosinophilia—Epirubicin—thyroid cancer	0.00152	0.00193	CcSEcCtD
Hydroxychloroquine—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00152	0.00193	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—PRKAR1A—thyroid cancer	0.00151	0.0071	CbGpPWpGaD
Hydroxychloroquine—Vomiting—Sorafenib—thyroid cancer	0.0015	0.00191	CcSEcCtD
Hydroxychloroquine—Abdominal pain upper—Doxorubicin—thyroid cancer	0.0015	0.00191	CcSEcCtD
Hydroxychloroquine—Rash—Sorafenib—thyroid cancer	0.00149	0.00189	CcSEcCtD
Hydroxychloroquine—Dermatitis—Sorafenib—thyroid cancer	0.00149	0.00189	CcSEcCtD
Hydroxychloroquine—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00148	0.00188	CcSEcCtD
Hydroxychloroquine—Headache—Sorafenib—thyroid cancer	0.00148	0.00188	CcSEcCtD
Hydroxychloroquine—Pancytopenia—Epirubicin—thyroid cancer	0.00146	0.00185	CcSEcCtD
Hydroxychloroquine—Muscular weakness—Doxorubicin—thyroid cancer	0.00145	0.00184	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—NRG1—thyroid cancer	0.00143	0.00674	CbGpPWpGaD
Hydroxychloroquine—TLR9—Innate Immune System—CDK1—thyroid cancer	0.00141	0.00663	CbGpPWpGaD
Hydroxychloroquine—Eosinophilia—Doxorubicin—thyroid cancer	0.00141	0.00179	CcSEcCtD
Hydroxychloroquine—Nausea—Sorafenib—thyroid cancer	0.0014	0.00178	CcSEcCtD
Hydroxychloroquine—Photosensitivity reaction—Epirubicin—thyroid cancer	0.0014	0.00178	CcSEcCtD
Hydroxychloroquine—Weight decreased—Epirubicin—thyroid cancer	0.00139	0.00176	CcSEcCtD
Hydroxychloroquine—Drowsiness—Epirubicin—thyroid cancer	0.00137	0.00174	CcSEcCtD
Hydroxychloroquine—TLR9—Innate Immune System—IFNA2—thyroid cancer	0.00136	0.00638	CbGpPWpGaD
Hydroxychloroquine—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00136	0.00172	CcSEcCtD
Hydroxychloroquine—Pancytopenia—Doxorubicin—thyroid cancer	0.00135	0.00171	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling by Insulin receptor—HRAS—thyroid cancer	0.00134	0.00628	CbGpPWpGaD
Hydroxychloroquine—TLR9—Toll-like Receptor Signaling Pathway—AKT1—thyroid cancer	0.00131	0.00615	CbGpPWpGaD
Hydroxychloroquine—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.0013	0.00165	CcSEcCtD
Hydroxychloroquine—TLR7—Regulation of toll-like receptor signaling pathway—AKT1—thyroid cancer	0.00129	0.00607	CbGpPWpGaD
Hydroxychloroquine—Weight decreased—Doxorubicin—thyroid cancer	0.00128	0.00163	CcSEcCtD
Hydroxychloroquine—Agranulocytosis—Epirubicin—thyroid cancer	0.00128	0.00162	CcSEcCtD
Hydroxychloroquine—Drowsiness—Doxorubicin—thyroid cancer	0.00127	0.00161	CcSEcCtD
Hydroxychloroquine—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00125	0.00159	CcSEcCtD
Hydroxychloroquine—Haemoglobin—Epirubicin—thyroid cancer	0.00123	0.00157	CcSEcCtD
Hydroxychloroquine—Haemorrhage—Epirubicin—thyroid cancer	0.00123	0.00156	CcSEcCtD
Hydroxychloroquine—TLR9—Immune System—TPR—thyroid cancer	0.00121	0.0057	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00121	0.00566	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—LGALS3—thyroid cancer	0.0012	0.00565	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—PRKAR1A—thyroid cancer	0.00119	0.00561	CbGpPWpGaD
Hydroxychloroquine—Visual impairment—Epirubicin—thyroid cancer	0.00118	0.0015	CcSEcCtD
Hydroxychloroquine—Agranulocytosis—Doxorubicin—thyroid cancer	0.00118	0.0015	CcSEcCtD
Hydroxychloroquine—Erythema multiforme—Epirubicin—thyroid cancer	0.00116	0.00147	CcSEcCtD
Hydroxychloroquine—Eye disorder—Epirubicin—thyroid cancer	0.00115	0.00146	CcSEcCtD
Hydroxychloroquine—Tinnitus—Epirubicin—thyroid cancer	0.00114	0.00145	CcSEcCtD
Hydroxychloroquine—Haemoglobin—Doxorubicin—thyroid cancer	0.00114	0.00145	CcSEcCtD
Hydroxychloroquine—Haemorrhage—Doxorubicin—thyroid cancer	0.00114	0.00144	CcSEcCtD
Hydroxychloroquine—TLR9—Innate Immune System—NRG1—thyroid cancer	0.00113	0.00532	CbGpPWpGaD
Hydroxychloroquine—Visual impairment—Doxorubicin—thyroid cancer	0.00109	0.00139	CcSEcCtD
Hydroxychloroquine—Alopecia—Epirubicin—thyroid cancer	0.00108	0.00138	CcSEcCtD
Hydroxychloroquine—Mental disorder—Epirubicin—thyroid cancer	0.00108	0.00137	CcSEcCtD
Hydroxychloroquine—Erythema multiforme—Doxorubicin—thyroid cancer	0.00107	0.00136	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—TCF7L1—thyroid cancer	0.00107	0.00504	CbGpPWpGaD
Hydroxychloroquine—Malnutrition—Epirubicin—thyroid cancer	0.00107	0.00136	CcSEcCtD
Hydroxychloroquine—Eye disorder—Doxorubicin—thyroid cancer	0.00106	0.00135	CcSEcCtD
Hydroxychloroquine—Tinnitus—Doxorubicin—thyroid cancer	0.00106	0.00135	CcSEcCtD
Hydroxychloroquine—Tension—Epirubicin—thyroid cancer	0.00105	0.00133	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—CDK1—thyroid cancer	0.00104	0.00489	CbGpPWpGaD
Hydroxychloroquine—Nervousness—Epirubicin—thyroid cancer	0.00104	0.00132	CcSEcCtD
Hydroxychloroquine—TLR9—Regulation of toll-like receptor signaling pathway—AKT1—thyroid cancer	0.00102	0.0048	CbGpPWpGaD
Hydroxychloroquine—Vision blurred—Epirubicin—thyroid cancer	0.00101	0.00128	CcSEcCtD
Hydroxychloroquine—Alopecia—Doxorubicin—thyroid cancer	0.001	0.00128	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—IFNA2—thyroid cancer	0.001	0.0047	CbGpPWpGaD
Hydroxychloroquine—Mental disorder—Doxorubicin—thyroid cancer	0.000995	0.00126	CcSEcCtD
Hydroxychloroquine—Malnutrition—Doxorubicin—thyroid cancer	0.000989	0.00126	CcSEcCtD
Hydroxychloroquine—Anaemia—Epirubicin—thyroid cancer	0.000988	0.00125	CcSEcCtD
Hydroxychloroquine—Agitation—Epirubicin—thyroid cancer	0.000982	0.00125	CcSEcCtD
Hydroxychloroquine—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000977	0.00459	CbGpPWpGaD
Hydroxychloroquine—Tension—Doxorubicin—thyroid cancer	0.00097	0.00123	CcSEcCtD
Hydroxychloroquine—Nervousness—Doxorubicin—thyroid cancer	0.00096	0.00122	CcSEcCtD
Hydroxychloroquine—Vertigo—Epirubicin—thyroid cancer	0.00096	0.00122	CcSEcCtD
Hydroxychloroquine—Leukopenia—Epirubicin—thyroid cancer	0.000957	0.00122	CcSEcCtD
Hydroxychloroquine—Loss of consciousness—Epirubicin—thyroid cancer	0.000939	0.00119	CcSEcCtD
Hydroxychloroquine—Vision blurred—Doxorubicin—thyroid cancer	0.000932	0.00118	CcSEcCtD
Hydroxychloroquine—Convulsion—Epirubicin—thyroid cancer	0.000926	0.00118	CcSEcCtD
Hydroxychloroquine—Anaemia—Doxorubicin—thyroid cancer	0.000914	0.00116	CcSEcCtD
Hydroxychloroquine—Agitation—Doxorubicin—thyroid cancer	0.000909	0.00115	CcSEcCtD
Hydroxychloroquine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000904	0.00115	CcSEcCtD
Hydroxychloroquine—Vertigo—Doxorubicin—thyroid cancer	0.000888	0.00113	CcSEcCtD
Hydroxychloroquine—Leukopenia—Doxorubicin—thyroid cancer	0.000885	0.00112	CcSEcCtD
Hydroxychloroquine—Oedema—Epirubicin—thyroid cancer	0.000872	0.00111	CcSEcCtD
Hydroxychloroquine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000869	0.0011	CcSEcCtD
Hydroxychloroquine—Convulsion—Doxorubicin—thyroid cancer	0.000857	0.00109	CcSEcCtD
Hydroxychloroquine—Nervous system disorder—Epirubicin—thyroid cancer	0.000855	0.00109	CcSEcCtD
Hydroxychloroquine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000854	0.00108	CcSEcCtD
Hydroxychloroquine—Skin disorder—Epirubicin—thyroid cancer	0.000847	0.00108	CcSEcCtD
Hydroxychloroquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000836	0.00106	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—NRG1—thyroid cancer	0.000835	0.00392	CbGpPWpGaD
Hydroxychloroquine—Anorexia—Epirubicin—thyroid cancer	0.000831	0.00106	CcSEcCtD
Hydroxychloroquine—TLR9—Immune System—CDK1—thyroid cancer	0.000822	0.00386	CbGpPWpGaD
Hydroxychloroquine—Oedema—Doxorubicin—thyroid cancer	0.000807	0.00103	CcSEcCtD
Hydroxychloroquine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000791	0.00101	CcSEcCtD
Hydroxychloroquine—TLR9—Immune System—IFNA2—thyroid cancer	0.000791	0.00372	CbGpPWpGaD
Hydroxychloroquine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00079	0.001	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—TSHR—thyroid cancer	0.000785	0.00369	CbGpPWpGaD
Hydroxychloroquine—Skin disorder—Doxorubicin—thyroid cancer	0.000784	0.000996	CcSEcCtD
Hydroxychloroquine—Somnolence—Epirubicin—thyroid cancer	0.000775	0.000985	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—PRKAR1A—thyroid cancer	0.000772	0.00363	CbGpPWpGaD
Hydroxychloroquine—Anorexia—Doxorubicin—thyroid cancer	0.000769	0.000977	CcSEcCtD
Hydroxychloroquine—Decreased appetite—Epirubicin—thyroid cancer	0.000758	0.000963	CcSEcCtD
Hydroxychloroquine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000753	0.000957	CcSEcCtD
Hydroxychloroquine—Fatigue—Epirubicin—thyroid cancer	0.000752	0.000955	CcSEcCtD
Hydroxychloroquine—Pain—Epirubicin—thyroid cancer	0.000746	0.000948	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—MEN1—thyroid cancer	0.000738	0.00347	CbGpPWpGaD
Hydroxychloroquine—TLR7—Innate Immune System—PTEN—thyroid cancer	0.000718	0.00337	CbGpPWpGaD
Hydroxychloroquine—Somnolence—Doxorubicin—thyroid cancer	0.000717	0.000911	CcSEcCtD
Hydroxychloroquine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000713	0.000906	CcSEcCtD
Hydroxychloroquine—Decreased appetite—Doxorubicin—thyroid cancer	0.000702	0.000891	CcSEcCtD
Hydroxychloroquine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000697	0.000885	CcSEcCtD
Hydroxychloroquine—Fatigue—Doxorubicin—thyroid cancer	0.000696	0.000884	CcSEcCtD
Hydroxychloroquine—Urticaria—Epirubicin—thyroid cancer	0.000693	0.00088	CcSEcCtD
Hydroxychloroquine—Pain—Doxorubicin—thyroid cancer	0.00069	0.000877	CcSEcCtD
Hydroxychloroquine—Abdominal pain—Epirubicin—thyroid cancer	0.00069	0.000876	CcSEcCtD
Hydroxychloroquine—Body temperature increased—Epirubicin—thyroid cancer	0.00069	0.000876	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—PTCH1—thyroid cancer	0.000667	0.00313	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—NRG1—thyroid cancer	0.00066	0.0031	CbGpPWpGaD
Hydroxychloroquine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00066	0.000838	CcSEcCtD
Hydroxychloroquine—Hypersensitivity—Epirubicin—thyroid cancer	0.000643	0.000816	CcSEcCtD
Hydroxychloroquine—Urticaria—Doxorubicin—thyroid cancer	0.000641	0.000814	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—NRAS—thyroid cancer	0.000641	0.00301	CbGpPWpGaD
Hydroxychloroquine—Abdominal pain—Doxorubicin—thyroid cancer	0.000638	0.00081	CcSEcCtD
Hydroxychloroquine—Body temperature increased—Doxorubicin—thyroid cancer	0.000638	0.00081	CcSEcCtD
Hydroxychloroquine—Asthenia—Epirubicin—thyroid cancer	0.000626	0.000795	CcSEcCtD
Hydroxychloroquine—Pruritus—Epirubicin—thyroid cancer	0.000617	0.000784	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—SST—thyroid cancer	0.00061	0.00287	CbGpPWpGaD
Hydroxychloroquine—Diarrhoea—Epirubicin—thyroid cancer	0.000597	0.000758	CcSEcCtD
Hydroxychloroquine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000595	0.000755	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—CALCA—thyroid cancer	0.000587	0.00276	CbGpPWpGaD
Hydroxychloroquine—Asthenia—Doxorubicin—thyroid cancer	0.000579	0.000736	CcSEcCtD
Hydroxychloroquine—Dizziness—Epirubicin—thyroid cancer	0.000577	0.000733	CcSEcCtD
Hydroxychloroquine—Pruritus—Doxorubicin—thyroid cancer	0.000571	0.000725	CcSEcCtD
Hydroxychloroquine—TLR9—Innate Immune System—PTEN—thyroid cancer	0.000568	0.00267	CbGpPWpGaD
Hydroxychloroquine—Vomiting—Epirubicin—thyroid cancer	0.000555	0.000705	CcSEcCtD
Hydroxychloroquine—Diarrhoea—Doxorubicin—thyroid cancer	0.000552	0.000701	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—KRAS—thyroid cancer	0.000551	0.00259	CbGpPWpGaD
Hydroxychloroquine—Rash—Epirubicin—thyroid cancer	0.00055	0.000699	CcSEcCtD
Hydroxychloroquine—Dermatitis—Epirubicin—thyroid cancer	0.000549	0.000698	CcSEcCtD
Hydroxychloroquine—Headache—Epirubicin—thyroid cancer	0.000546	0.000694	CcSEcCtD
Hydroxychloroquine—Dizziness—Doxorubicin—thyroid cancer	0.000534	0.000678	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—CDK1—thyroid cancer	0.000532	0.0025	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000519	0.00244	CbGpPWpGaD
Hydroxychloroquine—Nausea—Epirubicin—thyroid cancer	0.000518	0.000658	CcSEcCtD
Hydroxychloroquine—Vomiting—Doxorubicin—thyroid cancer	0.000513	0.000652	CcSEcCtD
Hydroxychloroquine—Rash—Doxorubicin—thyroid cancer	0.000509	0.000646	CcSEcCtD
Hydroxychloroquine—Dermatitis—Doxorubicin—thyroid cancer	0.000508	0.000646	CcSEcCtD
Hydroxychloroquine—TLR9—Innate Immune System—NRAS—thyroid cancer	0.000506	0.00238	CbGpPWpGaD
Hydroxychloroquine—Headache—Doxorubicin—thyroid cancer	0.000506	0.000642	CcSEcCtD
Hydroxychloroquine—Nausea—Doxorubicin—thyroid cancer	0.000479	0.000609	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—HRAS—thyroid cancer	0.000469	0.0022	CbGpPWpGaD
Hydroxychloroquine—TLR9—Innate Immune System—KRAS—thyroid cancer	0.000436	0.00205	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—NRG1—thyroid cancer	0.000427	0.00201	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—PTEN—thyroid cancer	0.000418	0.00197	CbGpPWpGaD
Hydroxychloroquine—TLR7—Innate Immune System—AKT1—thyroid cancer	0.000414	0.00194	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—TERT—thyroid cancer	0.000383	0.0018	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—MINPP1—thyroid cancer	0.000381	0.00179	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—NRAS—thyroid cancer	0.000373	0.00175	CbGpPWpGaD
Hydroxychloroquine—TLR9—Innate Immune System—HRAS—thyroid cancer	0.00037	0.00174	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—HIF1A—thyroid cancer	0.000366	0.00172	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—PTEN—thyroid cancer	0.000331	0.00155	CbGpPWpGaD
Hydroxychloroquine—TLR9—Innate Immune System—AKT1—thyroid cancer	0.000327	0.00154	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—NDUFA13—thyroid cancer	0.000324	0.00152	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—KRAS—thyroid cancer	0.000321	0.00151	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—CHST14—thyroid cancer	0.000305	0.00143	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—BRAF—thyroid cancer	0.000303	0.00143	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—NRAS—thyroid cancer	0.000295	0.00139	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—HRAS—thyroid cancer	0.000273	0.00128	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—KRAS—thyroid cancer	0.000254	0.00119	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—HPGD—thyroid cancer	0.000246	0.00115	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—AKT1—thyroid cancer	0.000241	0.00113	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—CCND1—thyroid cancer	0.000221	0.00104	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—HRAS—thyroid cancer	0.000216	0.00101	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—PTEN—thyroid cancer	0.000214	0.001	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—NRAS—thyroid cancer	0.000191	0.000896	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—AKT1—thyroid cancer	0.000191	0.000895	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—KRAS—thyroid cancer	0.000164	0.000771	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—TP53—thyroid cancer	0.000146	0.000685	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—TPR—thyroid cancer	0.000141	0.000663	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—HRAS—thyroid cancer	0.00014	0.000656	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	0.000139	0.000652	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—AKT1—thyroid cancer	0.000123	0.000579	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—SLC5A5—thyroid cancer	0.000106	0.000496	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—RXRA—thyroid cancer	8.88e-05	0.000417	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—PPARG—thyroid cancer	5.6e-05	0.000263	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—PTGS2—thyroid cancer	4.41e-05	0.000207	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—PTEN—thyroid cancer	3.85e-05	0.000181	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—AKT1—thyroid cancer	2.22e-05	0.000104	CbGpPWpGaD
